BiotechTube

Pirtobrutinib

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Chronic Lymphocytic Leukemia

Conditions

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma

Trial Timeline

May 20, 2025 → Dec 1, 2032

NCT ID
NCT06876649

About Pirtobrutinib

Pirtobrutinib is a approved stage product being developed by Eli Lilly for Chronic Lymphocytic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06876649. Target conditions include Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Lymphocytic Leukemia were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (11)

NCT IDPhaseStatus
NCT05172700Pre-clinicalCompleted
NCT07162181Phase 2Recruiting
NCT06876662ApprovedRecruiting
NCT06876649ApprovedRecruiting
NCT06812715Phase 2Recruiting
NCT06588478Phase 2Recruiting
NCT06258174Phase 1Completed
NCT06190678Phase 1Completed
NCT06180980Phase 1Completed
NCT06190691Phase 1Completed
NCT06181006Phase 1Completed

Competing Products

20 competing products in Chronic Lymphocytic Leukemia

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
25
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
19
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
30